COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials -
-
-
COMMUNIQUÉ DE PRESSE
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387 -
-
-
COMMUNIQUÉ DE PRESSE
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities
